Detecting Systemic Carbon Dioxide Levels With a Novel Biosensor (DISCO)

The Hospital of Vestfold

Status: Enrolling

Conditions: Neuromuscular Diseases; Obesity Hypoventilation Syndrome (OHS); Pulmonary Disease, Chronic Obstructive; Hypercapnic Respiratory Failure

Treatments: Device: IscAlert sensor

Study type: Observational

Funder types: Other

Identifiers

NCT06367686

REK KULMU B 714179

Details and patient eligibility

About

The study is an open, prospective, single center clinical observational pilot investigation. The aim is to compare the carbon dioxide values measured by the IscAlert sensor, which is inserted in proximity to the nasal mucosa. The study wants to investigate if the nasal mucosa application and measurements are feasible, what kind of possible complications such a measurement can cause, and if the measurements can be a surrogate marker for systemic carbon dioxide values.

Full description

he study is an open, prospective, single center clinical observational pilot investigation including 9 patients and 2 healthy volunteers. The aim is to compare the carbon dioxide values measured by the IscAlert sensor, which is inserted in proximity to the nasal mucosa, with the transcutaneous carbon dioxide values measured at the forehead by a transcutaneous carbon dioxide-monitor, the arterial carbon dioxide measurements performed by blood gas analyses, and carbon dioxide measurements registered with the IscAlert sensor implanted in the muscle of the forearm. The study wants to investigate if the nasal mucosa application and measurements are feasible, what kind of possible complications such a measurement can cause, and if the measurements can be a surrogate marker for systemic carbon dioxide values. The study will include patients with a tendency to hypoventilation, thereby giving rise to a carbon dioxide retention; 3 patients with chronic obstructive pulmonary disease with suspected hypercapnic respiratory failure who are evaluated for non-invasive mask-treatment and long-term oxygen treatment supply if needed. 3 patients with neuromuscular disorders and 3 patients with obesity hypoventilation syndrome who are evaluated for non-invasive mask treatment. The measurements will last for about 8 to 14 hours at night while the patients are sleeping. In addition, the study will also include 2 healthy volunteers as a control group. They will have the equipment mounted on them for about 8 hours during the day in connection with normal office work. Follow up by telephone 7 days +/-2 days after the measurements are finished. The inclusion period is expected to be about 9 months.

Enrollment: 11 estimated patients

Sex: All

Ages: 18 to 110 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

The subject must meet all of the following inclusion criteria at the time of enrolment:

EITHER

1. Patient are at risk of hypoventilation and thus carbon dioxide retention.

2. Either

   1. Under evaluation for treatment with non-invasive ventilation and maybe Long term oxygen treatment due to chronic obstructive pulmonary disease or
   2. Under evaluation for non-invasive ventilation support due to Obesity hypoventilation syndrome or due to a neuromuscular disorder.

   OR

3. Healthy volunteers

   ALL subjects:

4. Subject must be 18 years or older

5. Subject must be able to give written informed consent

Exclusion criteria

1. Known allergy to local anesthetics.
2. Participants should not have any kind of (direct or indirect) affiliation to Sensocure AS
3. Healthy volunteers: No heart-, lung-, or circulatory diseases, no bleeding disorder, no sleep disorders
4. Healthy volunteers should not have any kind of (direct or indirect) acquaintanceship to the investigators
5. Active smoker/use of snuff

Trial design

11 participants in 4 patient groups

Chronic obstructive pulmonary disease

Description:

3 Chronic obstructive pulmonary disease patients monitored with IscAlert sensor at nasal mucosa for 8-14 hours during the night

Treatment:

Device: IscAlert sensor

Neuromuscular disease

Description:

3 Neuromuscular disease patients monitored with IscAlert sensor at nasal mucosa for 8-14 hours during the night

Treatment:

Device: IscAlert sensor

Obesity hypoventilation syndrome

Description:

3 Obesity hypoventilation syndrome patients monitored with IscAlert sensor at nasal mucosa for 8-14 hours during the night

Treatment:

Device: IscAlert sensor

Healthy volunteers

Description:

2 healthy volunteers monitored with IscAlert sensor at nasal mucosa for approximately 8 hours during daytime

Treatment:

Device: IscAlert sensor